View ValuationEurofins Scientific 향후 성장Future 기준 점검 2/6Eurofins Scientific (는) 각각 연간 17.5% 및 5.9% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 17.4% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 14.5% 로 예상됩니다.핵심 정보17.5%이익 성장률17.36%EPS 성장률Life Sciences 이익 성장17.6%매출 성장률5.9%향후 자기자본이익률14.48%애널리스트 커버리지Good마지막 업데이트18 May 2026최근 향후 성장 업데이트공시 • Jul 23Eurofins Scientific SE Provides Earnings Guidance for Fiscal Year 2025 and for the Mid-Term to Fiscal Year 2027Eurofins Scientific SE provided earnings guidance for fiscal year 2025 and for the mid-term to fiscal year 2027. For 2025, the company targets mid-single-digit organic growth and potential revenues from acquisitions of €250 million consolidated at mid-year. For mid-term to fiscal year 2027, the company confirms its long-term average organic growth objective of 6.5% p.a. driven by secular growth trends in its end markets as well as its target for potential average revenues from acquisitions of €250 million p.a. over the period consolidated at mid-year.공시 • Jul 24Eurofins Scientific SE Provides Earnings Guidance for the Fiscal Year 2024Eurofins Scientific SE provided earnings guidance for the fiscal year 2024. For the year, the company expects revenues to be in the range of €7.075 billion to €7.175 billion.공시 • Jul 26Eurofins Scientific SE Updates Revenue Guidance for Fiscal Year 2023 and year 2027Eurofins Scientific SE has updated its objectives for Fiscal year 2023 and guidance for 2027. For the year, company expects Revenues to be €6.45 billion – €6.55 billion. For fiscal year, company expects Revenues to be Approaching €10 billion. The objectives for Fiscal Year 2027 have not been updated.모든 업데이트 보기Recent updates공시 • Mar 24Eurofins Scientific SE, Annual General Meeting, Apr 23, 2026Eurofins Scientific SE, Annual General Meeting, Apr 23, 2026, at 16:30 W. Europe Standard Time. Location: 2 4 rue d arlon, windhof Luxembourg공시 • Feb 10Eurofins Viracor BioPharma Expands Bioanalytical CapabilitiesEurofins Viracor BioPharma Services announced a significant expansion of its service portfolio with the addition of enhanced bioanalytical testing capabilities. These new services are fully aligned with Good Laboratory Practices (GLP) and Good Clinical Practices (GCP), enabling the company to enhance support of biopharmaceutical development programs with greater scientific breadth throughout the drug development workflow. This strategic advancement follows the successful relocation and integration of Eurofins Pharma Bioanalytics Services from St. Charles, Missouri, into Eurofins Viracor Bio Pharma's purpose-built, eleven-acre facility in Lenexa, Kansas. The bioanalytical organization brings more than two decades of specialized experience in pharmacokinetics, immunogenicity, and biomarker testing. By combining both laboratories' strengths, Eurofins ViracorBioPharma expands the depth of scientific expertise available to sponsors while simplifying access to integrated technologies, harmonized contracting, and comprehensive testing solutions under one unit; providing sponsors with more seamless and efficient experience. The newly expanded laboratory space in Lenexa was meticulously designed to meet the needs of increasingly complex clinical trials, ensuring high-quality sample management, streamlined workflows, and robust data integrity. With these enhanced capabilities, Eurofins Virac or BioPharma now offers a full suite of bioanalytical services, including method development, validation, and regulated sample analysis, all consistent with global regulatory guidance.공시 • Jan 29Eurofins Scientific SE Proposes Annual DividendEurofins Scientific SE announced that at the upcoming Annual General Meeting on 23 April 2026, the Board of Directors intends to propose an annual dividend of €0.72 per share, which is a year-on-year increase of 20%, and is in line with growth in Basic EPS8 attributable to owners of the Company. This payout would represent a split-adjusted 27% CAGR in the dividend per share, since Eurofins’ first dividend was declared for 2007.공시 • Jan 26Eurofins CDMO Alphora Announces Development & Implementation of AI-Powered Salt and Co-Crystal Screening SoftwareEurofins CDMO Alphora announced the development and launch of a new AI-powered software for high throughput salt and co-crystal screening - now a core component of all solid-state screening programs. Developed by Eurofins CDMO Alphora, in collaboration with a local university, this cutting-edge machine learning platform provides highly accurate predictions of salt and co-crystal formation for APIs and intermediates. This breakthrough technology streamlines solid form selection by minimizing trial and error experimentation, shortening development timelines, and lowering screening costs. With a user-friendly interface and advanced predictive models, the tool empowers clients to make smarter, data-driven decisions earlier in the drug substance development process --resulting in faster, more efficient delivery of optimized solid forms. Eurofins CDMO ALora's seasoned Solid-State R&D team guides partners and customers through every stage of salt and co-cry crystal development--from data interpretation to experimental strategy. Beyond salt and co-crystal work, the team is well positioned to address a full spectrum of solid-state challenges. Through close cross-departmental collaboration with drug product and drug substance development teams, Eurofins CDMO Alphore delivers fully integrated solutions to improve therapeutic bioavailability and manufacturing processing.공시 • Dec 23Eurofins Scientific SE to Report Fiscal Year 2025 Results on Jan 29, 2026Eurofins Scientific SE announced that they will report fiscal year 2025 results on Jan 29, 2026공시 • Dec 02Eurofins Medical Device Services North America Launches First GMP Pfas Screening and Testing Solutions for Medical DevicesEurofins Medical Device Services North America, part of a global network of over 20 medical device testing laboratories and a leading medical device solutions partner, recently launched a GMP PFAS testing and screening solution, the first developed and commercialized for the medical device industry. This offering provides insights to medical device manufacturers as they navigate the complex and evolving global regulations surrounding PFAS, ultimately contributing to medical device and patient safety. Eurofins Medical Device Services is setting new standards with the industry's first GMP PFAS testing and advanced PFAS Risk Assessments for medical devices. Per- and polyfluoroalkyl substances, or PFAS, are a group of more than twenty thousand chemical compounds which are highly resistant to degradation and have been found to pose potential threats to human health and the environment. Implementing PFAS testing in the early development stages allows medical device manufacturers to prepare for potential regulatory updates and avoid future shutdowns, recalls, and liability issues, while further supporting their sustainability goals.공시 • Jul 23Eurofins Scientific SE Provides Earnings Guidance for Fiscal Year 2025 and for the Mid-Term to Fiscal Year 2027Eurofins Scientific SE provided earnings guidance for fiscal year 2025 and for the mid-term to fiscal year 2027. For 2025, the company targets mid-single-digit organic growth and potential revenues from acquisitions of €250 million consolidated at mid-year. For mid-term to fiscal year 2027, the company confirms its long-term average organic growth objective of 6.5% p.a. driven by secular growth trends in its end markets as well as its target for potential average revenues from acquisitions of €250 million p.a. over the period consolidated at mid-year.공시 • May 21Eurofins Scientific SE (ENXTPA:ERF) acquired PLANTON GmbH from Michael Kleine and others.Eurofins Scientific SE (ENXTPA:ERF) acquired PLANTON GmbH from Michael Kleine and others on May 20, 2025. The Kiel site will not only remain intact it will even be expanded. The newly constructed laboratory building and the entire experienced Planton team will form the foundation for further growth under the Eurofins umbrella. Andreas Masuch of MELCHERS Rechtsanwälte acted as legal advisor and Consus Partner acted as financial advisor for PLANTON GmbH. Eurofins Scientific SE (ENXTPA:ERF) completed the acquisition of PLANTON GmbH from Michael Kleine and others on May 20, 2025.공시 • Apr 25Eurofins Scientific SE Proposes Annual Dividend, Payable on April 30, 2025Eurofins Scientific SE's Board of Directors proposed annual dividend of €0.60 per share, subject to approval at the upcoming Annual General Meeting on 24 April 2025 and payable on 30 April 2025.공시 • Apr 01Eurofins Scientific SE (ENXTPA:ERF) completed the acquisition of clinical diagnostics operations in Spain from SYNLAB AG (HMSE:SYAB).Eurofins Scientific SE (ENXTPA:ERF) agreed to acquire clinical diagnostics operations in Spain from SYNLAB AG (HMSE:SYAB) on October 28, 2024. For the period ending December 31, 2023, clinical diagnostics operations in Spain of SYNLAB AG reported total revenue of €140 million. The transaction is subject to customary conditions, including regulatory approvals, and is expected to close in 2025. Eurofins Scientific SE (ENXTPA:ERF) completed the acquisition of clinical diagnostics operations in Spain from SYNLAB AG (HMSE:SYAB) on March 31, 2025. With this acquisition, Eurofins will become a leading clinical diagnostics operator in Spain, with a unique capability to cater to public and private clients and cover all regions in the country.공시 • Mar 26Eurofins Scientific SE, Annual General Meeting, Apr 24, 2025Eurofins Scientific SE, Annual General Meeting, Apr 24, 2025.공시 • Dec 28Eurofins Scientific SE to Report Fiscal Year 2024 Results on Jan 30, 2025Eurofins Scientific SE announced that they will report fiscal year 2024 results on Jan 30, 2025공시 • Nov 09Eurofins Scientific SE to Report First Half, 2025 Results on Jul 24, 2025Eurofins Scientific SE announced that they will report first half, 2025 results on Jul 24, 2025공시 • Oct 28Eurofins Scientific SE (ENXTPA:ERF) agreed to acquire clinical diagnostics operations in Spain from SYNLAB AG (HMSE:SYAB).Eurofins Scientific SE (ENXTPA:ERF) agreed to acquire clinical diagnostics operations in Spain from SYNLAB AG (HMSE:SYAB) on October 28, 2024. For the period ending December 31, 2023, clinical diagnostics operations in Spain of SYNLAB AG reported total revenue of €140 million. The transaction is subject to customary conditions, including regulatory approvals, and is expected to close in 2025.공시 • Sep 17Eurofins Scientific SE (ENXTPA:ERF) acquired Infinity Laboratories, LLC from Imperial Capital Acquisition Fund VI and Imperial Capital Limited.Eurofins Scientific SE (ENXTPA:ERF) acquired Infinity Laboratories, LLC from Imperial Capital Acquisition Fund VI and Imperial Capital Limited on September 16, 2024. Eurofins Scientific SE (ENXTPA:ERF) completed the acquisition of Infinity Laboratories, LLC from Imperial Capital Acquisition Fund VI and Imperial Capital Limited on September 16, 2024.공시 • Jul 24Eurofins Scientific SE Provides Earnings Guidance for the Fiscal Year 2024Eurofins Scientific SE provided earnings guidance for the fiscal year 2024. For the year, the company expects revenues to be in the range of €7.075 billion to €7.175 billion.공시 • Apr 03Eurofins Scientific SE (ENXTPA:ERF) acquired Ascend Clinical, LLC.Eurofins Scientific SE (ENXTPA:ERF) acquired Ascend Clinical, LLC on April 3, 2024. Patti Hunsader, the current chief operating officer of Ascend, will assume the role of President of Ascend Clinical. The existing leadership of the company will remain in place, continuing to drive the organization's growth as part of the Eurofins clinical diagnostics business line in the United States. Eurofins Scientific SE (ENXTPA:ERF) completed the acquisition of Ascend Clinical, LLC on April 3, 2024.공시 • Mar 25Eurofins Scientific SE, Annual General Meeting, Apr 25, 2024Eurofins Scientific SE, Annual General Meeting, Apr 25, 2024, at 16:30 Central European Standard Time. Location: 2-4 Rue d’Arlon L-8399 Windhof Grand Duchy Of Luxemboug Luxembourg Agenda: To review of the management report prepared by the board of directors, including the group management report, the special report on the conflicts of interest and the special report on the buy-back of its own shares for the financial year ended 31 December 2023; to review of the special report on the transactions carried-out in the context of the authorized share capital; to review the report of the approved statutory auditor on the annual statutory accounts prepared in accordance with the laws and regulations of the Grand Duchy of Luxembourg, the consolidated financial statements prepared in accordance with the IFRS for the financial year ended 31 December 2023, and on the performance of its mission; to approve the consolidated financial statements and the annual statutory accounts for the financial year ended 31 December 2023; ; to approve the allocation of net profit for the financial year ended 31 December 2023; and to consider other matters.공시 • Jul 26Eurofins Scientific SE Updates Revenue Guidance for Fiscal Year 2023 and year 2027Eurofins Scientific SE has updated its objectives for Fiscal year 2023 and guidance for 2027. For the year, company expects Revenues to be €6.45 billion – €6.55 billion. For fiscal year, company expects Revenues to be Approaching €10 billion. The objectives for Fiscal Year 2027 have not been updated.공시 • Jun 09Eurofins Scientific SE to Report First Half, 2023 Results on Jul 26, 2023Eurofins Scientific SE announced that they will report first half, 2023 results on Jul 26, 2023공시 • Oct 04Eurofins Scientific SE to Report Fiscal Year 2022 Results on Feb 21, 2023Eurofins Scientific SE announced that they will report fiscal year 2022 results on Feb 21, 2023이익 및 매출 성장 예측OTCPK:ERFS.F - 애널리스트 향후 추정치 및 과거 재무 데이터 (EUR Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/20288,6727949271,6881012/31/20278,0596758221,6171212/31/20267,5885167191,3711112/31/20257,2964165641,399N/A9/30/20257,2203996741,357N/A6/30/20257,1443817841,315N/A3/31/20257,0483697871,317N/A12/31/20246,9513567911,319N/A9/30/20246,8373417321,267N/A6/30/20246,7243266741,215N/A3/31/20246,6192915711,117N/A12/31/20236,5152574681,018N/A9/30/20236,512335403995N/A6/30/20236,510414339971N/A3/31/20236,6114974071,054N/A12/31/20226,7125814761,136N/A9/30/20226,7856126021,219N/A6/30/20226,8576437271,301N/A3/31/20226,7876968661,406N/A12/31/20216,7187491,0051,511N/A9/30/20216,5537861,0231,499N/A6/30/20216,3888241,0411,487N/A3/31/20215,9136659551,355N/A12/31/20205,4395058681,224N/A9/30/20205,0793477131,057N/A6/30/20204,719190558891N/A3/31/20204,641168457784N/A12/31/20194,563146355678N/A9/30/20194,384144N/A618N/A6/30/20194,205143N/A558N/A3/31/20193,993159N/A551N/A12/31/20183,781175N/A544N/A9/30/20183,549182N/A521N/A6/30/20183,318190N/A498N/A3/31/20183,145185N/A451N/A12/31/20172,971179N/A405N/A9/30/20172,848166N/A387N/A6/30/20172,725152N/A369N/A3/31/20172,631145N/A370N/A12/31/20162,537138N/A372N/A9/30/20162,427104N/A350N/A6/30/20162,31769N/A328N/A3/31/20162,13363N/A310N/A12/31/20151,95056N/A291N/A9/30/20151,77971N/A274N/A6/30/20151,60986N/A256N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: ERFS.F 의 연간 예상 수익 증가율(17.5%)이 saving rate(3.5%)보다 높습니다.수익 vs 시장: ERFS.F 의 연간 수익(17.5%)이 US 시장(16.8%)보다 빠르게 성장할 것으로 예상됩니다.고성장 수익: ERFS.F 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.수익 대 시장: ERFS.F 의 수익(연간 5.9%)이 US 시장(연간 11.7%)보다 느리게 성장할 것으로 예상됩니다.고성장 매출: ERFS.F 의 수익(연간 5.9%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: ERFS.F의 자본 수익률은 3년 후 14.5%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/26 15:49종가2026/05/22 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Eurofins Scientific SE는 34명의 분석가가 다루고 있습니다. 이 중 12명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관James Rowland ClarkBarclaysJames RosenthalBarclaysCarl RaynsfordBerenberg31명의 분석가 더 보기
공시 • Jul 23Eurofins Scientific SE Provides Earnings Guidance for Fiscal Year 2025 and for the Mid-Term to Fiscal Year 2027Eurofins Scientific SE provided earnings guidance for fiscal year 2025 and for the mid-term to fiscal year 2027. For 2025, the company targets mid-single-digit organic growth and potential revenues from acquisitions of €250 million consolidated at mid-year. For mid-term to fiscal year 2027, the company confirms its long-term average organic growth objective of 6.5% p.a. driven by secular growth trends in its end markets as well as its target for potential average revenues from acquisitions of €250 million p.a. over the period consolidated at mid-year.
공시 • Jul 24Eurofins Scientific SE Provides Earnings Guidance for the Fiscal Year 2024Eurofins Scientific SE provided earnings guidance for the fiscal year 2024. For the year, the company expects revenues to be in the range of €7.075 billion to €7.175 billion.
공시 • Jul 26Eurofins Scientific SE Updates Revenue Guidance for Fiscal Year 2023 and year 2027Eurofins Scientific SE has updated its objectives for Fiscal year 2023 and guidance for 2027. For the year, company expects Revenues to be €6.45 billion – €6.55 billion. For fiscal year, company expects Revenues to be Approaching €10 billion. The objectives for Fiscal Year 2027 have not been updated.
공시 • Mar 24Eurofins Scientific SE, Annual General Meeting, Apr 23, 2026Eurofins Scientific SE, Annual General Meeting, Apr 23, 2026, at 16:30 W. Europe Standard Time. Location: 2 4 rue d arlon, windhof Luxembourg
공시 • Feb 10Eurofins Viracor BioPharma Expands Bioanalytical CapabilitiesEurofins Viracor BioPharma Services announced a significant expansion of its service portfolio with the addition of enhanced bioanalytical testing capabilities. These new services are fully aligned with Good Laboratory Practices (GLP) and Good Clinical Practices (GCP), enabling the company to enhance support of biopharmaceutical development programs with greater scientific breadth throughout the drug development workflow. This strategic advancement follows the successful relocation and integration of Eurofins Pharma Bioanalytics Services from St. Charles, Missouri, into Eurofins Viracor Bio Pharma's purpose-built, eleven-acre facility in Lenexa, Kansas. The bioanalytical organization brings more than two decades of specialized experience in pharmacokinetics, immunogenicity, and biomarker testing. By combining both laboratories' strengths, Eurofins ViracorBioPharma expands the depth of scientific expertise available to sponsors while simplifying access to integrated technologies, harmonized contracting, and comprehensive testing solutions under one unit; providing sponsors with more seamless and efficient experience. The newly expanded laboratory space in Lenexa was meticulously designed to meet the needs of increasingly complex clinical trials, ensuring high-quality sample management, streamlined workflows, and robust data integrity. With these enhanced capabilities, Eurofins Virac or BioPharma now offers a full suite of bioanalytical services, including method development, validation, and regulated sample analysis, all consistent with global regulatory guidance.
공시 • Jan 29Eurofins Scientific SE Proposes Annual DividendEurofins Scientific SE announced that at the upcoming Annual General Meeting on 23 April 2026, the Board of Directors intends to propose an annual dividend of €0.72 per share, which is a year-on-year increase of 20%, and is in line with growth in Basic EPS8 attributable to owners of the Company. This payout would represent a split-adjusted 27% CAGR in the dividend per share, since Eurofins’ first dividend was declared for 2007.
공시 • Jan 26Eurofins CDMO Alphora Announces Development & Implementation of AI-Powered Salt and Co-Crystal Screening SoftwareEurofins CDMO Alphora announced the development and launch of a new AI-powered software for high throughput salt and co-crystal screening - now a core component of all solid-state screening programs. Developed by Eurofins CDMO Alphora, in collaboration with a local university, this cutting-edge machine learning platform provides highly accurate predictions of salt and co-crystal formation for APIs and intermediates. This breakthrough technology streamlines solid form selection by minimizing trial and error experimentation, shortening development timelines, and lowering screening costs. With a user-friendly interface and advanced predictive models, the tool empowers clients to make smarter, data-driven decisions earlier in the drug substance development process --resulting in faster, more efficient delivery of optimized solid forms. Eurofins CDMO ALora's seasoned Solid-State R&D team guides partners and customers through every stage of salt and co-cry crystal development--from data interpretation to experimental strategy. Beyond salt and co-crystal work, the team is well positioned to address a full spectrum of solid-state challenges. Through close cross-departmental collaboration with drug product and drug substance development teams, Eurofins CDMO Alphore delivers fully integrated solutions to improve therapeutic bioavailability and manufacturing processing.
공시 • Dec 23Eurofins Scientific SE to Report Fiscal Year 2025 Results on Jan 29, 2026Eurofins Scientific SE announced that they will report fiscal year 2025 results on Jan 29, 2026
공시 • Dec 02Eurofins Medical Device Services North America Launches First GMP Pfas Screening and Testing Solutions for Medical DevicesEurofins Medical Device Services North America, part of a global network of over 20 medical device testing laboratories and a leading medical device solutions partner, recently launched a GMP PFAS testing and screening solution, the first developed and commercialized for the medical device industry. This offering provides insights to medical device manufacturers as they navigate the complex and evolving global regulations surrounding PFAS, ultimately contributing to medical device and patient safety. Eurofins Medical Device Services is setting new standards with the industry's first GMP PFAS testing and advanced PFAS Risk Assessments for medical devices. Per- and polyfluoroalkyl substances, or PFAS, are a group of more than twenty thousand chemical compounds which are highly resistant to degradation and have been found to pose potential threats to human health and the environment. Implementing PFAS testing in the early development stages allows medical device manufacturers to prepare for potential regulatory updates and avoid future shutdowns, recalls, and liability issues, while further supporting their sustainability goals.
공시 • Jul 23Eurofins Scientific SE Provides Earnings Guidance for Fiscal Year 2025 and for the Mid-Term to Fiscal Year 2027Eurofins Scientific SE provided earnings guidance for fiscal year 2025 and for the mid-term to fiscal year 2027. For 2025, the company targets mid-single-digit organic growth and potential revenues from acquisitions of €250 million consolidated at mid-year. For mid-term to fiscal year 2027, the company confirms its long-term average organic growth objective of 6.5% p.a. driven by secular growth trends in its end markets as well as its target for potential average revenues from acquisitions of €250 million p.a. over the period consolidated at mid-year.
공시 • May 21Eurofins Scientific SE (ENXTPA:ERF) acquired PLANTON GmbH from Michael Kleine and others.Eurofins Scientific SE (ENXTPA:ERF) acquired PLANTON GmbH from Michael Kleine and others on May 20, 2025. The Kiel site will not only remain intact it will even be expanded. The newly constructed laboratory building and the entire experienced Planton team will form the foundation for further growth under the Eurofins umbrella. Andreas Masuch of MELCHERS Rechtsanwälte acted as legal advisor and Consus Partner acted as financial advisor for PLANTON GmbH. Eurofins Scientific SE (ENXTPA:ERF) completed the acquisition of PLANTON GmbH from Michael Kleine and others on May 20, 2025.
공시 • Apr 25Eurofins Scientific SE Proposes Annual Dividend, Payable on April 30, 2025Eurofins Scientific SE's Board of Directors proposed annual dividend of €0.60 per share, subject to approval at the upcoming Annual General Meeting on 24 April 2025 and payable on 30 April 2025.
공시 • Apr 01Eurofins Scientific SE (ENXTPA:ERF) completed the acquisition of clinical diagnostics operations in Spain from SYNLAB AG (HMSE:SYAB).Eurofins Scientific SE (ENXTPA:ERF) agreed to acquire clinical diagnostics operations in Spain from SYNLAB AG (HMSE:SYAB) on October 28, 2024. For the period ending December 31, 2023, clinical diagnostics operations in Spain of SYNLAB AG reported total revenue of €140 million. The transaction is subject to customary conditions, including regulatory approvals, and is expected to close in 2025. Eurofins Scientific SE (ENXTPA:ERF) completed the acquisition of clinical diagnostics operations in Spain from SYNLAB AG (HMSE:SYAB) on March 31, 2025. With this acquisition, Eurofins will become a leading clinical diagnostics operator in Spain, with a unique capability to cater to public and private clients and cover all regions in the country.
공시 • Mar 26Eurofins Scientific SE, Annual General Meeting, Apr 24, 2025Eurofins Scientific SE, Annual General Meeting, Apr 24, 2025.
공시 • Dec 28Eurofins Scientific SE to Report Fiscal Year 2024 Results on Jan 30, 2025Eurofins Scientific SE announced that they will report fiscal year 2024 results on Jan 30, 2025
공시 • Nov 09Eurofins Scientific SE to Report First Half, 2025 Results on Jul 24, 2025Eurofins Scientific SE announced that they will report first half, 2025 results on Jul 24, 2025
공시 • Oct 28Eurofins Scientific SE (ENXTPA:ERF) agreed to acquire clinical diagnostics operations in Spain from SYNLAB AG (HMSE:SYAB).Eurofins Scientific SE (ENXTPA:ERF) agreed to acquire clinical diagnostics operations in Spain from SYNLAB AG (HMSE:SYAB) on October 28, 2024. For the period ending December 31, 2023, clinical diagnostics operations in Spain of SYNLAB AG reported total revenue of €140 million. The transaction is subject to customary conditions, including regulatory approvals, and is expected to close in 2025.
공시 • Sep 17Eurofins Scientific SE (ENXTPA:ERF) acquired Infinity Laboratories, LLC from Imperial Capital Acquisition Fund VI and Imperial Capital Limited.Eurofins Scientific SE (ENXTPA:ERF) acquired Infinity Laboratories, LLC from Imperial Capital Acquisition Fund VI and Imperial Capital Limited on September 16, 2024. Eurofins Scientific SE (ENXTPA:ERF) completed the acquisition of Infinity Laboratories, LLC from Imperial Capital Acquisition Fund VI and Imperial Capital Limited on September 16, 2024.
공시 • Jul 24Eurofins Scientific SE Provides Earnings Guidance for the Fiscal Year 2024Eurofins Scientific SE provided earnings guidance for the fiscal year 2024. For the year, the company expects revenues to be in the range of €7.075 billion to €7.175 billion.
공시 • Apr 03Eurofins Scientific SE (ENXTPA:ERF) acquired Ascend Clinical, LLC.Eurofins Scientific SE (ENXTPA:ERF) acquired Ascend Clinical, LLC on April 3, 2024. Patti Hunsader, the current chief operating officer of Ascend, will assume the role of President of Ascend Clinical. The existing leadership of the company will remain in place, continuing to drive the organization's growth as part of the Eurofins clinical diagnostics business line in the United States. Eurofins Scientific SE (ENXTPA:ERF) completed the acquisition of Ascend Clinical, LLC on April 3, 2024.
공시 • Mar 25Eurofins Scientific SE, Annual General Meeting, Apr 25, 2024Eurofins Scientific SE, Annual General Meeting, Apr 25, 2024, at 16:30 Central European Standard Time. Location: 2-4 Rue d’Arlon L-8399 Windhof Grand Duchy Of Luxemboug Luxembourg Agenda: To review of the management report prepared by the board of directors, including the group management report, the special report on the conflicts of interest and the special report on the buy-back of its own shares for the financial year ended 31 December 2023; to review of the special report on the transactions carried-out in the context of the authorized share capital; to review the report of the approved statutory auditor on the annual statutory accounts prepared in accordance with the laws and regulations of the Grand Duchy of Luxembourg, the consolidated financial statements prepared in accordance with the IFRS for the financial year ended 31 December 2023, and on the performance of its mission; to approve the consolidated financial statements and the annual statutory accounts for the financial year ended 31 December 2023; ; to approve the allocation of net profit for the financial year ended 31 December 2023; and to consider other matters.
공시 • Jul 26Eurofins Scientific SE Updates Revenue Guidance for Fiscal Year 2023 and year 2027Eurofins Scientific SE has updated its objectives for Fiscal year 2023 and guidance for 2027. For the year, company expects Revenues to be €6.45 billion – €6.55 billion. For fiscal year, company expects Revenues to be Approaching €10 billion. The objectives for Fiscal Year 2027 have not been updated.
공시 • Jun 09Eurofins Scientific SE to Report First Half, 2023 Results on Jul 26, 2023Eurofins Scientific SE announced that they will report first half, 2023 results on Jul 26, 2023
공시 • Oct 04Eurofins Scientific SE to Report Fiscal Year 2022 Results on Feb 21, 2023Eurofins Scientific SE announced that they will report fiscal year 2022 results on Feb 21, 2023